UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 94

Sortiert nach

[177Lu]-PSMA-617 radionuclide treatment in patients with metastatic castration-resistant prostate cancer (LuPSMA trial): a single-centre, single-arm, phase 2 study

The lancet oncology, 2018-06, Vol.19 (6), p.825-833

2018

Link zum Volltext

Verfügbarkeit prüfen

Prognostic biomarkers in men with metastatic castration-resistant prostate cancer receiving [177Lu]-PSMA-617

European journal of nuclear medicine and molecular imaging, 2020-09, Vol.47 (10), p.2322-2327

2020

Link zum Volltext

Verfügbarkeit prüfen

Actinium-225 Prostate-specific Membrane Antigen Theranostics: Will α Beat β?

European urology, 2021-03, Vol.79 (3), p.351-352

2021

Link zum Volltext

Verfügbarkeit prüfen

The added benefit of contrast-enhanced CT in evaluation of incidental FDG-avid colon lesions

European journal of nuclear medicine and molecular imaging, 2020-09, Vol.47 (10), p.2244-2244

2020

Link zum Volltext

Verfügbarkeit prüfen

Out with the Old, in with the New: Can We Bridge the Gap Between Clinical Trial Results Based on Bone Scans and the Era of Modern Prostate Cancer Imaging?

Journal of Nuclear Medicine, 2023-11, Vol.64 (11), p.1748-1749

2023

Link zum Volltext

Verfügbarkeit prüfen

Characteristics and outcomes of therapy-related myeloid neoplasms after peptide receptor radionuclide/chemoradionuclide therapy (PRRT/PRCRT) for metastatic neuroendocrine neoplasia: a single-institution series

European journal of nuclear medicine and molecular imaging, 2019-08, Vol.46 (9), p.1902-1910

2019

Link zum Volltext

Verfügbarkeit prüfen

Preoperative Positron Emission Tomography for Node-Positive Head and Neck Cutaneous Squamous Cell Carcinoma

Otolaryngology-head and neck surgery, 2018-01, Vol.158 (1), p.122-126

2018

Link zum Volltext

Verfügbarkeit prüfen

A role of PSMA PET/CT in multimodality imaging approach in adenoid cystic carcinoma

Journal of medical imaging and radiation oncology, 2021-04, Vol.65 (2), p.213-215

2021

Link zum Volltext

Verfügbarkeit prüfen

Could FAP-Targeted Molecular Imaging Replace 18 F-FDG for Standard-of-Care Oncologic PET?

Journal of Nuclear Medicine, 2023-04, Vol.64 (4), p.623-624

2023

Link zum Volltext

Verfügbarkeit prüfen

Unraveling the Impact of 177 Lu-PSMA Radioligand Therapy on Renal Impairment: Distinguishing Causation from Correlation

Journal of Nuclear Medicine, 2024-01, Vol.65 (1), p.85-86

2024

Link zum Volltext

Verfügbarkeit prüfen

FDG PET in follicular lymphoma: more than a staging test?

Leukemia & lymphoma, 2017-07, Vol.58 (7), p.1521-1523

2017

Link zum Volltext

Verfügbarkeit prüfen

Optical Differentiation Between Malignant and Benign Lymphadenopathy by Grey Scale Texture Analysis of Endobronchial Ultrasound Convex Probe Images

Chest, 2012-03, Vol.141 (3), p.709-715

2012

Link zum Volltext

Verfügbarkeit prüfen

Radiation Dosimetry in 177Lu-PSMA-617 Therapy

Seminars in nuclear medicine, 2022-03, Vol.52 (2), p.243-254

2022

Link zum Volltext

Verfügbarkeit prüfen

Could FAP-Targeted Molecular Imaging Replace 18F-FDG for Standard-of-Care Oncologic PET?

The Journal of nuclear medicine (1978), 2023-04, Vol.64 (4), p.623-624

2023

Link zum Volltext

Verfügbarkeit prüfen

Mechanistic Insights for Optimizing PSMA Radioligand Therapy

Clinical cancer research, 2020-06, Vol.26 (12), p.2774-2776

2020

Link zum Volltext

Verfügbarkeit prüfen

Efficacy of Peptide Receptor Radionuclide Therapy for Esthesioneuroblastoma

Journal of Nuclear Medicine, 2020-09, Vol.61 (9), p.1326-1330

2020

Link zum Volltext

Verfügbarkeit prüfen

PSMA and FDG-PET as predictive and prognostic biomarkers in patients given [177Lu]Lu-PSMA-617 versus cabazitaxel for metastatic castration-resistant prostate cancer (TheraP): a biomarker analysis from a randomised, open-label, phase 2 trial

The lancet oncology, 2022-11, Vol.23 (11), p.1389-1397

2022

Link zum Volltext

Verfügbarkeit prüfen

FDG PET/CT Appearance of Benign Pilomatricoma

Clinical nuclear medicine, 2012-07, Vol.37 (7), p.684-686

2012

Link zum Volltext

Verfügbarkeit prüfen

Splenunculus masquerading as a neuroendocrine tumor of the pancreatic allograft in a kidney-pancreas recipient

Transplantation, 2013-10, Vol.96 (8), p.e59

2013

Link zum Volltext

Verfügbarkeit prüfen

FDG-avid lesions on PET scans without corresponding pathological findings

Journal of gastroenterology, 2012-06, Vol.47 (6), p.726-727

2012

Link zum Volltext

Verfügbarkeit prüfen

Prostate-specific membrane antigen PET/computed tomography for staging prostate cancer

Current opinion in urology, 2020-09, Vol.30 (5), p.628

2020

Link zum Volltext

Verfügbarkeit prüfen

Setting the stage: Contemporary staging of non-melanomatous skin cancer and implementation of the new American Joint Committee on cancer eighth edition staging manual

Oral oncology, 2019-11, Vol.98, p.102-108

2019

Link zum Volltext

Verfügbarkeit prüfen

The Role of 68Ga-DOTA-Octreotate PET/CT in Follow-Up of SDH-Associated Pheochromocytoma and Paraganglioma

The journal of clinical endocrinology and metabolism, 2019-11, Vol.104 (11), p.5091-5099

2019

Link zum Volltext

Verfügbarkeit prüfen

Poor Outcomes for Patients with Metastatic Castration-resistant Prostate Cancer with Low Prostate-specific Membrane Antigen (PSMA) Expression Deemed Ineligible for 177Lu-labelled PSMA Radioligand Therapy

European urology oncology, 2019-11, Vol.2 (6), p.670-676

2019

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 94

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(87)
Mit Volltextzugriff
(90)

Publikationsform

Sprache

Erscheinungsjahr

n.n

Thema

Science & Technology
(55)
Life Sciences & Biomedicine
(47)
Humans
(42)
Male
(29)
Middle Aged
(16)
Radiology, Nuclear Medicine & Medical Imaging
(16)
Female
(15)
Positron-Emission Tomography
(14)
Tomography, X-Ray Computed
(14)
Fluorodeoxyglucose F18
(13)
Aged
(12)
Adult
(11)
Metastases
(11)
Oncology
(11)
Prostate Cancer
(11)
Patients
(10)
Positron Emission Tomography
(10)
Metastasis
(9)
Treatment Outcome
(9)
Aged, 80 And Over
(8)

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(3)

Menü

Weitere Dienste

Einstellungen

[177Lu]-PSMA-617 radionuclide treatment in patients with metastatic castration-resistant prostate cancer (LuPSMA trial): a single-centre, single-arm, phase 2 study

Prognostic biomarkers in men with metastatic castration-resistant prostate cancer receiving [177Lu]-PSMA-617

Actinium-225 Prostate-specific Membrane Antigen Theranostics: Will α Beat β?

The added benefit of contrast-enhanced CT in evaluation of incidental FDG-avid colon lesions

Out with the Old, in with the New: Can We Bridge the Gap Between Clinical Trial Results Based on Bone Scans and the Era of Modern Prostate Cancer Imaging?

Characteristics and outcomes of therapy-related myeloid neoplasms after peptide receptor radionuclide/chemoradionuclide therapy (PRRT/PRCRT) for metastatic neuroendocrine neoplasia: a single-institution series

Prostate-specific Membrane Antigen Positron Emission Tomography–detected Disease Extent and Overall Survival of Patients with High-risk Nonmetastatic Castration-resistant Prostate Cancer: An International Multicenter Retrospective Study

Preoperative Positron Emission Tomography for Node-Positive Head and Neck Cutaneous Squamous Cell Carcinoma

A role of PSMA PET/CT in multimodality imaging approach in adenoid cystic carcinoma

Could FAP-Targeted Molecular Imaging Replace 18 F-FDG for Standard-of-Care Oncologic PET?

Unraveling the Impact of 177 Lu-PSMA Radioligand Therapy on Renal Impairment: Distinguishing Causation from Correlation

FDG PET in follicular lymphoma: more than a staging test?

Optical Differentiation Between Malignant and Benign Lymphadenopathy by Grey Scale Texture Analysis of Endobronchial Ultrasound Convex Probe Images

Radiation Dosimetry in 177Lu-PSMA-617 Therapy

Could FAP-Targeted Molecular Imaging Replace 18F-FDG for Standard-of-Care Oncologic PET?

Mechanistic Insights for Optimizing PSMA Radioligand Therapy

Efficacy of Peptide Receptor Radionuclide Therapy for Esthesioneuroblastoma

PSMA and FDG-PET as predictive and prognostic biomarkers in patients given [177Lu]Lu-PSMA-617 versus cabazitaxel for metastatic castration-resistant prostate cancer (TheraP): a biomarker analysis from a randomised, open-label, phase 2 trial

FDG PET/CT Appearance of Benign Pilomatricoma

Splenunculus masquerading as a neuroendocrine tumor of the pancreatic allograft in a kidney-pancreas recipient

FDG-avid lesions on PET scans without corresponding pathological findings

Prostate-specific membrane antigen PET/computed tomography for staging prostate cancer

Setting the stage: Contemporary staging of non-melanomatous skin cancer and implementation of the new American Joint Committee on cancer eighth edition staging manual

The Role of 68Ga-DOTA-Octreotate PET/CT in Follow-Up of SDH-Associated Pheochromocytoma and Paraganglioma

Poor Outcomes for Patients with Metastatic Castration-resistant Prostate Cancer with Low Prostate-specific Membrane Antigen (PSMA) Expression Deemed Ineligible for 177Lu-labelled PSMA Radioligand Therapy

Suchergebnisse filtern